Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer).

Future oncology (London, England)·2026
Same author

Corrigendum to "Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes" [Eur J Cancer (May) (2025) 15:221:115404].

European journal of cancer (Oxford, England : 1990)·2026
Same author

Assessment of cytotoxicity and genomic instability induced by coal-derived nanoparticles in V79 and HaCaT Cells.

Archives of toxicology·2026
Same author

Insights into the Chemico-Biological Interactions of Natural Sesquiterpene Lactones with the Thiol-Redox Metabolism of Pathogenic Trypanosomatids.

ChemMedChem·2026
Same author

Versatile Magneto-Dielectric Response of Epitaxial Thin Films of the High Entropy Oxide Perovskite Nd(Cr<sub>0.2</sub>Mn<sub>0.2</sub>Fe<sub>0.2</sub>Co<sub>0.2</sub>Ni<sub>0.2</sub>)O<sub>3</sub>.

Advanced materials (Deerfield Beach, Fla.)·2026
Same author

In situ detection of methyl jasmonate using plant-wearable sensors to quantify genotype-dependent herbivory resistance.

Biosensors & bioelectronics·2026

Related Experiment Video

Updated: Jun 22, 2026

Mouse Bladder Wall Injection
03:48

Mouse Bladder Wall Injection

Published on: July 12, 2011

24.2K

New Nitric Oxide-Releasing Compounds as Promising Anti-Bladder Cancer Drugs.

María Varela1,2, Miriam López1,2, Mariana Ingold2

  • 1Departamento de Genética, Instituto de Investigaciones Biológicas Clemente Estable, Avenida Italia 3318, Montevideo 11600, Uruguay.

Biomedicines
|January 21, 2023
PubMed
Summary

Nitric oxide-releasing compounds 1 and 3 show significant potential against bladder cancer by inhibiting cell growth and reducing survivin. Compound 3 also decreased cancer cell migration, offering new therapeutic avenues.

Keywords:
NF-κBbladder cancerfuroxansnitric oxide donorssurvivin

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.6K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.3K

Related Experiment Videos

Last Updated: Jun 22, 2026

Mouse Bladder Wall Injection
03:48

Mouse Bladder Wall Injection

Published on: July 12, 2011

24.2K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.6K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.3K

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Bladder cancer presents a significant global health challenge requiring novel therapeutic strategies.
  • Existing treatments necessitate the development of new compounds with improved efficacy.

Purpose of the Study:

  • To investigate the antitumor potential of three novel nitric oxide-releasing compounds against bladder cancer.
  • To evaluate the antiproliferative, antimigratory, and genotoxic effects of these compounds on bladder cancer cell lines.

Main Methods:

  • Utilized T24 and 253J bladder cancer cell lines to assess compound effects.
  • Determined compound-induced DNA damage, NF-κB pathway inhibition, and survivin downregulation.
  • Evaluated the impact of compounds on cell proliferation and migration.

Main Results:

  • Compounds 1 and 3 demonstrated potent antiproliferative activity against bladder cancer cells.
  • Both compounds induced DNA damage and downregulated survivin expression.
  • Compound 3 significantly inhibited bladder cancer cell migration.

Conclusions:

  • Nitric oxide donors show promise as a new therapeutic approach for bladder cancer.
  • These compounds target key mechanisms in tumorigenesis and cancer progression.
  • Further development of these molecules could lead to novel bladder cancer treatments.